CTLA 4 News and Research

RSS

Neoadjuvant trial of combination immunotherapy has favorable outcomes in bladder cancer patients

Neoadjuvant, or pre-surgical, combination treatment with the immune checkpoint inhibitors tremelimumab (anti-CTLA-4) and durvalumab (anti-PD-1) was well-tolerated and showed early signs of activity in certain patients with localized bladder cancer who do not have standard treatment options available, according to a Phase I clinical trial conducted by The University of Texas MD Anderson Cancer Center.

13 Oct 2020

New biomarker may help identify patients at risk for graft-versus-host disease after stem cell transplants

A recent report published in Science Translational Medicine by MUSC Hollings Cancer Center investigator Sophie Paczesny, M.D., Ph.D., sheds light on immune cell biomarkers that may reveal which patients are most at risk for graft-versus-host disease (GVHD), a life-threatening condition that can arise after hematopoietic stem cell transplantation (HSCT) for treatment of liquid cancers such as leukemia.

7 Oct 2020

Ludwig study uncovers a nutritional approach to improve cancer immunotherapy

A Ludwig Cancer Research study has uncovered a mechanism by which the tumor's harsh internal environment sabotages T lymphocytes, leading cellular agents of the anticancer immune response.

5 Oct 2020

Antibody improves progression-free survival in patients with advanced prostate cancer

An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer.

29 Sep 2020

Engineered, high-affinity ACE2 receptors neutralize SARS-CoV-2

In a study published in the preprint server bioRxiv, researchers from the Kyoto Prefectural University of Medicine and Osaka University Japan, discuss how they engineered ACE2 to enhance its affinity to RBD in human cells.

17 Sep 2020

Study sheds light on how interferon-gamma drives response to immunotherapy in melanoma

A new study by researchers at the UCLA Jonsson Comprehensive Cancer Center sheds light on how interferon-gamma (IFN-y), an immune response-stimulating signaling molecule that helps activate immune cells, guides the treatment response in people with advanced melanoma who are treated with one of the leading immunotherapies -; immune checkpoint blockade.

10 Sep 2020

Harbour BioMed and Viva Biotech announce strategic collaboration to promote incubation of biotech startups

Harbour BioMed, a global clinical stage biopharmaceutical company and Viva Biotech (Shanghai) Ltd., a world-leading structure-based drug discovery platform today announced a strategic partnership under which both parties will collate their respective expertise in drug discovery and development to promote the incubation of innovative biotech startups.

31 Jul 2020

Dysfunctional T cells present at high levels in severe COVID-19

Now, a new study by researchers at Saarland University, Germany, and published on the preprint server medRxiv in July 2020 shows that there are higher levels of anti-SARS-CoV-2 T cells, which show significant alterations in the phenotype and function.

12 Jul 2020

SWOG scientists to deliver online presentations at ASCO20 Virtual Scientific Program

Researchers from SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, will make 31 presentations as part of the ASCO20 Virtual Scientific Program, the online annual meeting of the American Society of Clinical Oncology (ASCO), which runs May 29-31.

19 May 2020

Bio-Rad Introduces Anti-Ipilimumab Antibodies

Bio-Rad Laboratories, Inc has extended its range of recombinant monoclonal anti-idiotypic antibodies.

21 Apr 2020

Immunotherapy may benefit mCRPC patients with specific markers of immune activation

Although metastatic castration-resistant prostate cancer typically has limited response to immunotherapy, a subset of patients with pretreatment evidence of active T-cell responses in their tumors experienced prolonged survival following treatment with ipilimumab in a Phase II trial at The University of Texas MD Anderson Cancer Center.

1 Apr 2020

Immunotherapy combination can shrink viral reservoir in HIV model

Stimulating immune cells with two cancer immunotherapies together can shrink the size of the viral "reservoir" in SIV-infected non-human primates treated with antiviral drugs, researchers have concluded.

16 Mar 2020

Levels of sBTLA proteins may be a marker of overall survival in patients with HCC

In the 2020 February 25 issue of Scientific Reports, a research group from the Department of Hepatology in Osaka City University Graduate School of Medicine, Japan reported that levels of a circulating soluble immune checkpoint protein can be used as a potential marker to predict overall survival in patients with advanced HCC.

9 Mar 2020

Pre-operative immunotherapy can elicit an immune response that shrinks oral cancers

A new clinical trial suggests that immunotherapy given before other treatments for oral cavity cancers can elicit an immune response that shrinks tumors, which could provide long-term benefit for patients.

27 Feb 2020

Immunotherapy drug combination effective for patients with fast-growing neuroendocrine tumors

Many patients with rare, fast-growing neuroendocrine tumors respond well to a common immunotherapy drug combination, according to the first peer-reviewed publication out of DART, short for Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors, a unique rare cancer clinical trial.

24 Feb 2020

Using newly discovered immune cell type to fight pancreatic cancer

Immunotherapy is showing great promise for treating cancer. But so far, this approach has been effective in only about 20% of all cancers. To advance those results, researchers are looking for new ways to mobilize the immune system to destroy tumors.

23 Feb 2020

Researchers engineer probiotics to safely deliver immunotherapies to tumors

Researchers at Columbia Engineering have engineered probiotics to safely deliver immunotherapies within tumors.

12 Feb 2020

Immunosupressant combination therapy for glioblastoma shows promise

Researchers from the University of Texas have found an immunosuppressing target for the treatment of glioblastoma. In mice studies the team has identified CD73 macrophages which could be used to treat the cancers. The team also performed studies on human tumours to arrive at their conclusions. The study was published in the latest issue of the journal Nature Medicine this week.

23 Dec 2019

Transitional T cells could help improve cancer immunotherapy

In chronic viral infections and cancer, T cell dysfunction is sure to be observed. A new study to be published in the journal Immunity shows that before these cells are completely exhausted, there is a transitory stage in which some cells are present with features that are characteristic of neither the stem-like T cells nor the mature but exhausted T cells.

4 Dec 2019

New method for discovering potential cancer-treating compounds

A new study published in the journal Cell Reports reports a novel method by which antitumor drugs that focus on reawakening exhausted immune cells called cytotoxic T cells against cancer can be quickly identified. This could help treat a large subset of cancers that thrive because of their ability to suppress antitumor activity in T cells.